Cardiovascular risk, atherosclerosis and metabolic syndrome after liver transplantation: A mini review

Expert Review of Gastroenterology and Hepatology

Volumn 7, Issue 4, 2013, Pages 361-364

  Oliveira, Claudia Pinto Marques Souza De ^a   Stefano, Jose Tadeu ^a   Álvares Da Silva, Mário Reis ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

atherosclerosis; cardiovascular risk; diabetes mellitus; dyslipidemia; hypertension; immunosuppression; inappropriate diet; liver transplantation; metabolic syndrome; sedentary

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ABDOMINAL OBESITY; ACUTE LIVER FAILURE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC LIVER FAILURE; DIABETES MELLITUS; DIET; DRUG DOSE REDUCTION; DYSLIPIDEMIA; GRAFT RECIPIENT; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RESISTANCE; KIDNEY INJURY; LIFE EXPECTANCY; LIPID PEROXIDATION; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; OXIDATIVE STRESS; PREVALENCE; REVIEW; SEDENTARY LIFESTYLE; SIDE EFFECT; SMOKING; SURGICAL TECHNIQUE; SURVIVAL;

ATHEROSCLEROSIS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; HUMANS; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; SURVIVORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84877275477     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.13.19     Document Type: Review

References (30)

1. Desai S, Hong JC, Saab S. Cardiovascular risk factors following orthotopic liver transplantation: predisposing factors, incidence and management. Liver Int. 30(7), 948-957 (2010).
2. Stravitz RT, Carl DE, Biskobing DM. Medical management of the liver transplant recipient. Clin. Liver Dis. 15(4), 821-843 (2011).
3. Hanouneh IA, Feldstein AE, McCullough AJ et al. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl. 14(9), 1287-1293 (2008).
4. Albeldawi M, Aggarwal A, Madhwal S et al. Cumulative risk of cardiovascular events after orthotopic liver transplantation. Liver Transpl. 18(3), 370-375 (2012).
5. Watt KD, Charlton MR. Metabolic syndrome and liver transplantation: a review and guide to management. J. Hepatol. 53(1), 199-206 (2010).
6. Raval Z, Harinstein ME, Skaro AI et al. Cardiovascular risk assessment of the liver transplant candidate. J. Am. Coll. Cardiol. 58(3), 223-231 (2011).
7. Pagadala M, Dasarathy S, Eghtesad B, McCullough AJ. Posttransplant metabolic syndrome: an epidemic waiting to happen. Liver Transpl. 15(12), 1662-1670 (2009).
8. Hryniewiecka E, Zegarska J, Paczek L. Arterial hypertension in liver transplant recipients. Transplant. Proc. 43(8), 3029-3034 (2011).
9. Sheiner PA, Magliocca JF, Bodian CA et al. Long-term medical complications in patients surviving > or = 5 years after liver transplant. Transplantation 69(5), 781-789 (2000).
10. Munoz SJ, Deems RO, Moritz MJ, Martin P, Jarrell BE, Maddrey WC. Hyperlipidemia and obesity after orthotopic liver transplantation. Transplant. Proc. 23(1 Pt 2), 1480-1483 (1991).
11. Everhart JE, Lombardero M, Lake JR, Wiesner RH, Zetterman RK, Hoofnagle JH. Weight change and obesity after liver transplantation: incidence and risk factors. Liver Transpl. Surg. 4(4), 285-296 (1998).
12. Laryea M, Watt KD, Molinari M et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl. 13(8), 1109-1114 (2007).
13. Laish I, Braun M, Mor E, Sulkes J, Harif Y, Ben Ari Z. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. Liver Transpl. 17(1), 15-22 (2011).
14. Afzali A, Berry K, Ioannou GN. Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. Liver Transpl. 18(1), 29-37 (2012).
15. Claes K, Meier-Kriesche HU, Schold JD, Vanrenterghem Y, Halloran PF, Ekberg H. Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study. Nephrol. Dial. Transplant. 27(2), 850-857 (2012).
16. Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am. J. Transplant. 2(9), 807-818 (2002).
17. Muñoz SJ. Hyperlipidemia and other coronary risk factors after orthotopic liver transplantation: pathogenesis, diagnosis, and management. Liver Transpl. Surg. 1(5 Suppl. 1), 29-38 (1995).
18. Rike AH, Mogilishetty G, Alloway RR et al. Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplantation: comparison of early steroid withdrawal and chronic steroids. Clin. Transplant. 22(2), 229-235 (2008).
19. Segev DL, Sozio SM, Shin EJ et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl. 14(4), 512-525 (2008).
20. Watt KD. Metabolic syndrome: is immunosuppression to blame? Liver Transpl. 17(Suppl. 3), S38-S42 (2011).
21. Madhwal S, Atreja A, Albeldawi M et al. Is liver transplantation a risk factor for cardiovascular disease? A meta-analysis of observational studies. Liver Transpl. 18(10), 1140-1146 (2012).
22. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J. Am. Coll. Cardiol. 49(21), 2129-2138 (2007).
23. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 97(18), 1837-1847 (1998).
24. Alvares-da-Silva MR, Oliveira CP, Stefano JT et al. Conventional and novel cardiovascular risk factors in liver transplant recipients. J. Hepatol. 56(3), S75-S76 (2012).
25. Oliveira CP, Kappel CR, Siqueira ER et al. Effects of hepatitis C virus on cardiovascular risk in infected patients: a comparative study. Int. J. Cardiol. 164(2), 221-226 (2013).
26. Coss E, Watt KD, Pedersen R, Dierkhising R, Heimbach JK, Charlton MR. Predictors of cardiovascular events after liver transplantation: a role for pretransplant serum troponin levels. Liver Transpl. 17(1), 23-31 (2011).
27. Grundy SM, Balady GJ, Criqui MH et al. Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. Circulation 97(18), 1876-1887 (1998).
28. Grundy SM, Cleeman JI, Merz CN et al.; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110(2), 227-239 (2004).
29. Newsome PN, Allison ME, Andrews PA et al.; British Transplant Society. Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis. Gut 61(4), 484-500 (2012).
30. Anastácio LR, Ferreira LG, Ribeiro Hde S, Liboredo JC, Lima AS, Correia MI. Metabolic syndrome after liver transplantation: prevalence and predictive factors. Nutrition 27(9), 931-937 (2011).